Initial treatment of cancer patients with fluconazole susceptible dose-dependent Candida glabrata fungemia: Better outcome with an echinocandin or polyene compared to an azole? [PublishAheadOfPrint]

28-day crude mortality in 68 cancer patients with fluconazole susceptible dose-dependent Candida glabrata fungemia started on treatment (within 48 hours after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%), compared to those treated with azole monotherapy (52%, p=0.07). After adjusting for confounders, azole monotherapy was associated with worse 28-day survival (hazard ratio 3.8, p=0.003).

http://ift.tt/2sxyiy5